CN103536601B - Preparation method of medicine used for controlling pasteurella infection of livestock and poultry - Google Patents
Preparation method of medicine used for controlling pasteurella infection of livestock and poultry Download PDFInfo
- Publication number
- CN103536601B CN103536601B CN201310482347.XA CN201310482347A CN103536601B CN 103536601 B CN103536601 B CN 103536601B CN 201310482347 A CN201310482347 A CN 201310482347A CN 103536601 B CN103536601 B CN 103536601B
- Authority
- CN
- China
- Prior art keywords
- powder
- sulfachlorpyridazine sodium
- compound
- parts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 17
- 206010034107 Pasteurella infections Diseases 0.000 title abstract description 12
- 201000005115 pasteurellosis Diseases 0.000 title abstract description 12
- 244000144977 poultry Species 0.000 title abstract description 8
- 244000144972 livestock Species 0.000 title abstract description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000000843 powder Substances 0.000 claims abstract description 39
- ODWMXYHUKDMPTR-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(6-chloropyridazin-3-yl)azanide Chemical compound [Na+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=CC=C(Cl)N=N1 ODWMXYHUKDMPTR-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 229960000905 indomethacin Drugs 0.000 claims abstract description 25
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 19
- 239000011591 potassium Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000375 suspending agent Substances 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 17
- 229910052708 sodium Inorganic materials 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 17
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 13
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000440 bentonite Substances 0.000 claims description 12
- 229910000278 bentonite Inorganic materials 0.000 claims description 12
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 229910052710 silicon Inorganic materials 0.000 claims description 12
- 239000010703 silicon Substances 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 7
- 229940085605 saccharin sodium Drugs 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 241001465754 Metazoa Species 0.000 abstract description 6
- 239000003651 drinking water Substances 0.000 abstract description 4
- 235000020188 drinking water Nutrition 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 230000003260 anti-sepsis Effects 0.000 abstract 1
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229960001031 glucose Drugs 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 206010035664 Pneumonia Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 5
- 241000272525 Anas platyrhynchos Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000027954 Poultry disease Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000193395 Sporosarcina pasteurii Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 201000006509 pleuropneumonia Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- ASFHDLDAWYTMJS-UHFFFAOYSA-N 3-methoxypyridazine Chemical compound COC1=CC=CN=N1 ASFHDLDAWYTMJS-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011509 Crystalluria Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- WMPXPUYPYQKQCX-UHFFFAOYSA-N Sulfamonomethoxine Chemical compound C1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 WMPXPUYPYQKQCX-UHFFFAOYSA-N 0.000 description 1
- 229920001617 Vinyon Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229950003874 sulfamonomethoxine Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to compound sulfachlorpyridazine sodium powder, and specifically provides a preparation method of compound sulfachlorpyridazine sodium powder used for controlling pasteurella infection of livestock and poultry. 100 parts of the compound sulfachlorpyridazine sodium powder comprise 60 to 65 parts of sulfachlorpyridazine sodium, 2 to 4 parts of indometacin potassium, 10 to 25 parts of a suspending agent, 2 to 4 parts of a corrigent and the balance an acceptable carrier. The ingredients above are mixed and grinded so as to obtain the compound sulfachlorpyridazine sodium powder. The compound sulfachlorpyridazine sodium powder possesses accurate curative effects on pasteurellosis of a plurality of animals, and is suitable for popularization and application in livestock breeding. According to the preparation method, sulfachlorpyridazine sodium and indometacin potassium are used together, besides antisepsis and anti-inflammation effects, indometacin potassium is used as an antibacterial synergist of sulfachlorpyridazine sodium, so that synergistic effect is achieved, and pharmacological function of the main medicine is improved. Absorptivity of the compound sulfachlorpyridazine sodium powder, which can be taken orally, or mixed with feed for use, or dissolved in drinking water for use, is high; drug tolerance is difficult to be caused; the compound sulfachlorpyridazine sodium powder is safe to be used for protection, prevention and therapy in a long term. Palatability, fluidity and suspending water solubility are excellent; clinical administration methods are diverse; and the compound sulfachlorpyridazine sodium powder is convenient for clinical administration.
Description
The application is application number: 201210358062.0, and patent name is: the divisional application of the patent of invention of " a kind of preparation method of Compound Sulfachorpyrdazine Sodium Powder ", the original bill applying date: on JIUYUE 24th, 2012.
Technical field
The present invention relates to a kind of Compound Sulfachorpyrdazine Sodium Powder, also relate to the medicine of control poultry pasteurella infection.
Background technology
Prinzone (Squibb) antimicrobial spectrum is similar to sulfamonomethoxine, is one of sulphonamides that vivo bacteria corrosion action is the strongest, has comparatively high inhibition effect to most of gram positive bacteria and negative bacterium, and it is slower that antibacterial produces drug resistance to this medicine.Blood drug level is high, and acetyl rate is low, not easily produces crystalluria.
Bacillus pasteurii disease is a kind of septic infectious disease of the many animals caused by pasteurella multocida.When weather, seasonal variations, long-distance transport and the factor such as parasitic infection, malnutrition cause animal body resistance to reduce, Fit First animal respiratory and the interior existing pasteurellosis bacillus of tonsil will become strong toadstool and cause autogenous infection.In addition can because the feedstuff, water, air, utensil etc. polluted be through digestive tract, respiratory tract, wound and cause exogenous infection.Because infective agent ubiquity, the normal acute attack of primary disease, the sick fowl of most acute can without any symptom, and several lower wing of flapping suddenly falls down to the ground death, and affected animal is in the majority for age with children, and comparatively seriously, case fatality rate is high.
The medicine of the control poultry pasteurella infection needing a kind of effect more definite in prior art.Meanwhile, the Prinzone (Squibb) powder preparation of poultry pasteurella infection is not is not prevented and treated in prior art yet.
Summary of the invention
Main purpose of the present invention is to provide a kind of preparation method of the Compound Sulfachorpyrdazine Sodium Powder for preventing and treating poultry pasteurella infection.
The technical solution adopted in the present invention is: a kind of preparation method of Compound Sulfachorpyrdazine Sodium Powder, is characterized in that:
Formula:
Preparation process:
A, the suspending agent getting recipe quantity are pulverized, and cross 80 eye mesh screens, be then uniformly mixed after pulverizing, and check the opaque uniformity without decorative pattern without mottle, obtain A powder, for subsequent use; Usual incorporation time is about 15min;
B, the Prinzone (Squibb) getting recipe quantity, indomethacin potassium and correctives are pulverized, and cross 80 eye mesh screens, be then uniformly mixed after pulverizing, and the inspection opaque uniformity without mottle, obtains B powder without decorative pattern; Usual incorporation time is about 15min;
C, above-mentioned B powder added in A powder by the equivalent method of progressively increasing stir, then add enough other carriers acceptable and continue to be uniformly mixed, check that the opaque uniformity crosses 80 eye mesh screens without decorative pattern without after mottle, to obtain final product; Usual incorporation time is about 15min.
During subpackage, can fill in vinyon bottle, polyethylene plastic bag, loading amount comprises 100g, 200g, 500g etc.
Further, described correctives is sucrose and/or saccharin sodium.
Further, described suspending agent is one or more in silicon Bentonite, sodium citrate, sodium carboxymethyl cellulose.
Further, described suspending agent is the mixture of silicon Bentonite 5 ~ 10 parts, sodium citrate 5 ~ 10 parts, sodium carboxymethyl cellulose 3 ~ 5 parts.
Further, described acceptable carrier is anhydrous glucose or soluble starch.
Product prepared by the inventive method shows following technical advantage in practice:
1, there is definite curative effect to the Bacillus pasteurii disease of many animals, be suitable for promoting the use of in livestock culture.The present invention adopts Prinzone (Squibb) and indomethacin potassium compatibility to use, and while anti-inflammation, indomethacin potassium is as the Trimethoprim of Prinzone (Squibb), can produce the drug effect that synergism strengthens principal agent.Oral, mixed feeding, drinking-water absorb well and not easily produce drug resistance, long-term care Prevention and Curation use safety.
2, the Compound Sulfachorpyrdazine Sodium Powder of novel process technology preparation has good palatability, mobility and suspendible water solublity, ensures that this product clinical administration is various and convenient.Correctives can cover the bitterness of Prinzone (Squibb), indomethacin potassium completely, can be directly oral; The adjuvant of the selected suitable particle diameter of prescription makes finished product have good mobility, is convenient to Homogeneous phase mixing, and mixed fodder is fed also very safe; Meanwhile, this product is also dry suspension, easily topple over after dissolving, sedimentation slowly, jolting energy redispersion gently after sedimentation, and the size of suspended particles after dissolving remains unchanged in long-term storage in water.This in turn ensures effectiveness and the safety of drinking-water use.
The theoretical foundation of the product that the present invention obtains may be: technical scheme of the present invention has better played the effect of indomethacin potassium.Indomethacin (Indomethacin) has obvious potent effect to some antibiotic or antimicrobial drug.Because lung tissue is tissue basophil, when pulmonary is inflamed, the sulfa drugs of some antibiotic of indomethacin portability as high dose preferentially arrives infection site, and high concentration is gathered in inflammatory tissue cell peripheral, indomethacin can make sulfa drugs concentration in infected tissue improve 4 ~ 8 times, and after coupling, anti-infectives use amount can reduce by half and even can be only 1/4 of positive usual amounts.This Synergistic Mechanisms is different from the mechanism of action of trimethoprim.Indomethacin also has significant antiinflammatory, antipyretic and analgesic activity.Its antiinflammation is the strongest in anti-inflammation drugs.It is to pig height febrile illness antipyretic and anti-inflammatory, chicks thoracic cavity infection, duck infectious bronchitis and poultry pneumonia, hydrothorax and Combination pneumonia have significant adjuvant treatment effect, and this may have obviously potent relevant with antiinflammation with indomethacin.
Detailed description of the invention
The principal agent Prinzone (Squibb) (anhydride meter content is 99.8%) used in embodiment is purchased from Zhuhai Yuan Cheng medication chemistry company limited; Indomethacin potassium (anhydride meter content is 99.1%) is purchased from Ou Yi Shi Pharmaceutical Group Pharmaceutical Co; Soluble starch, anhydrous glucose, sucrose and saccharin sodium are purchased from Henan navigator's chemical products company limited; Silicon Bentonite, sodium citrate, sodium carboxymethyl cellulose (AR) are purchased from Hua Heng bio tech ltd of Jizhou City.
Embodiment one
1, formula
Prinzone (Squibb) 60g, indomethacin potassium 2g, silicon Bentonite 5g, sodium citrate 5g, sodium carboxymethyl cellulose 3g, saccharin sodium 2g, soluble starch 23g.
2: preparation method
The first step: get the silicon Bentonite of recipe quantity, sodium citrate, sodium carboxymethyl cellulose pulverize, cross 80 eye mesh screens after pulverizing, be then uniformly mixed 15min, obtain without the A powder of decorative pattern without mottle;
Second step: get the Prinzone (Squibb) of recipe quantity, indomethacin potassium and saccharin sodium and pulverize, crosses 80 eye mesh screens after pulverizing, is then uniformly mixed 15min, obtains without the B powder of decorative pattern without mottle;
3rd step: above-mentioned B powder is added in A powder by the equivalent method of progressively increasing and stirs, then add enough soluble starches and continue to be uniformly mixed 15min.Check and confirm that the opaque uniformity crosses 80 eye mesh screens without decorative pattern without after mottle, obtain Compound Sulfachorpyrdazine Sodium Powder.
Embodiment two
1, formula
Prinzone (Squibb) 62.5g, indomethacin potassium 3g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 12.5g.
2: preparation method: identical with method described in embodiment 1, only correctives saccharin sodium is changed to sucrose, other carrier being soluble starch is changed to anhydrous glucose.
Embodiment three
1, formula
Prinzone (Squibb) 65g, indomethacin potassium 4g, silicon Bentonite 10g, sodium citrate 10g, sodium carboxymethyl cellulose 5g, sucrose 4g, anhydrous glucose 2g.
2: preparation method: identical with method described in embodiment 1, only correctives saccharin sodium is changed to sucrose, other carrier being soluble starch is changed to anhydrous glucose.
The stability test of Compound Sulfachorpyrdazine Sodium Powder
1, materials and methods: the Compound Sulfachorpyrdazine Sodium Powder of Example 1-3, hot and humid high light Acceleration study is carried out according to " Chinese veterinary pharmacopoeia " version in 2010 annex medicine stability experimental technique, by commercially available back, place 6 months in the medicine stability experimental box (Chongqing immortality experimental apparatus factory) of temperature 40 ± 2 DEG C, relative humidity 75 ± 5%, illumination 4500 ± 500LX, sample respectively once 1st, 2,3,6 the end of month at experimental session, the character of powder, content, granularity, appearance uniform degree, sedimentation volume ratio, redispersibility are investigated.
2, result: as shown in Table 1, Compound Sulfachorpyrdazine Sodium Powder of the present invention is in accelerated test after 6 months, character, content, granularity, appearance uniform degree, sedimentation volume ratio, redispersibility have no significant change, have good stability, meet " Chinese veterinary pharmacopoeia " version in 2010 completely to the quality index requirement of dry suspension.
The Acceleration study result of table 1, Compound Sulfachorpyrdazine Sodium Powder of the present invention
Compound Sulfachorpyrdazine Sodium Powder is at veterinary clinic effect
1. materials and methods
1.1 medicine
Compound Sulfachorpyrdazine Sodium Powder of the present invention, adopts the embodiment of the present invention 2 product.
1.2 cases sources: technical staff in Hechuan, Tongliang County, the area such as Tongnan gather clinical in pasteurella infection natural occurrence case, is respectively duck infectious bronchitis 337 example, chicken pneumonia 3625 example, rabbit snuffles 284 example, piglet pleuropneumonia 235 example, chicken cholera 2780 example, baby swine paratyphoid 332 example, acute fibrinous pleurisy 101 example of cattle.
1.3 case diagnosis: with natural cases according to epidemiology, clinical symptoms, pathological change, Laboratory Diagnosed.Comprehensive analysis, is diagnosed as pasteurella infection case.
1.4 implementation processes: carry out case selection by this seminar technical staff and implement treatment, and log.
1.5 results judge
Usage and dosage: natural cases used by drinking-water is for oral administration, a secondary amounts, every 1kg body weight, pig, cattle 20 ~ 30mg, be used in conjunction 6; Chicken, duck, rabbit 20 ~ 30mg, be used in conjunction 4.Observe after one week, pay a return visit and record the state of an illness.
Cure: medication 3 ~ 4 future trouble poultry diseases disappear completely, and spirit, body temperature, appetite recover normal, and urine feces is normal.
Effective: medication 3 ~ 4 future trouble poultry diseases disappear substantially, and spirit, body temperature, appetite make moderate progress, and urine feces is normal.
Invalid: medication 4 future trouble poultry diseases do not disappear, and sb.'s illness took a turn for the worse or death, and urine stool colour, character are abnormal.
2. result: compound sulfamethoxazole methoxy pyridazine injection of the present invention has good therapeutic effect as can be seen from Table 2, more than 96.0% is reached to effective percentage such as duck infectious bronchitis, chicken pneumonia, rabbit snuffles, piglet pleuropneumonia, chicken cholera, baby swine paratyphoid, the acute fibrinous pleurisies of cattle, cure rate all more than 92%, and has specially good effect to chicken cholera, chicken pneumonia.
Table 2: Compound Sulfachorpyrdazine Sodium Powder clinical therapeutic efficacy statistical table of the present invention
Compound Sulfachorpyrdazine Sodium Powder of the present invention adopts Prinzone (Squibb) and the composite effect achieving enhancing evident in efficacy of indomethacin potassium.And the consumption of indomethacin potassium needs to be strict with in formula, can only select at this particular range.
For verifying this technique effect, carry out contrast test.
The formula of comparative example 1: Prinzone (Squibb) 62.5g, indomethacin potassium 1g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 14.5g.
The formula of comparative example 2: Prinzone (Squibb) 62.5g, indomethacin potassium 6g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 9.5g.
The formula of comparative example 3: Prinzone (Squibb) 62.5g, indomethacin potassium 10g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 5.5g.
Preparation method is identical with embodiment 1.
Implement the product of 2 and the product of comparative example 1,2,3, the curative effect being used for the treatment of pasteurella infection case by same usage and dosage is as shown in table 3, and visible formula of the present invention achieves significant technique effect.
The statistical effect table of table 3 product of the present invention and contrast product clinical treatment chicken pneumonia
Claims (3)
1. a preparation method for Compound Sulfachorpyrdazine Sodium Powder, is characterized in that:
Formula is:
Described suspending agent is one or more in silicon Bentonite, sodium citrate, sodium carboxymethyl cellulose;
Preparation process:
A, the suspending agent getting recipe quantity are pulverized, and cross 80 eye mesh screens, be then uniformly mixed after pulverizing, and check the opaque uniformity without decorative pattern without mottle, obtain A powder, for subsequent use;
B, the Prinzone (Squibb) getting recipe quantity, indomethacin potassium and correctives are pulverized, and cross 80 eye mesh screens, be then uniformly mixed after pulverizing, and the inspection opaque uniformity without mottle, obtains B powder without decorative pattern, for subsequent use;
C, above-mentioned B powder added in A powder by the equivalent method of progressively increasing stir, then add enough other carriers acceptable and continue to be uniformly mixed, check that the opaque uniformity crosses 80 eye mesh screens without decorative pattern without after mottle, to obtain final product.
2. the preparation method of a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 1, is characterized in that: described correctives is sucrose and/or saccharin sodium.
3. the preparation method of a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 1, is characterized in that: described suspending agent is the mixture of silicon Bentonite 5 ~ 7.5 parts, sodium citrate 5 ~ 7.5 parts, sodium carboxymethyl cellulose 3 ~ 4 parts
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310482347.XA CN103536601B (en) | 2012-09-24 | 2012-09-24 | Preparation method of medicine used for controlling pasteurella infection of livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310482347.XA CN103536601B (en) | 2012-09-24 | 2012-09-24 | Preparation method of medicine used for controlling pasteurella infection of livestock and poultry |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210358062.0A Division CN102860984B (en) | 2012-09-24 | 2012-09-24 | Method for preparing compound sulfachloropyridazine sodium powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103536601A CN103536601A (en) | 2014-01-29 |
| CN103536601B true CN103536601B (en) | 2015-05-13 |
Family
ID=49960716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310482347.XA Expired - Fee Related CN103536601B (en) | 2012-09-24 | 2012-09-24 | Preparation method of medicine used for controlling pasteurella infection of livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103536601B (en) |
-
2012
- 2012-09-24 CN CN201310482347.XA patent/CN103536601B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| Ralph D.Feigin et.al.无.《Textbook of Pediatric Infectious Diseases》.2004,第2卷(第5版),3013. * |
| 吲哚美辛在畜禽疾病中的应用;徐艳;《养殖技术顾问》;20101231(第3期);164 * |
| 易本驰等.复方磺胺氯达嗪粉.《养猪科学用药指南》.2009,196. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103536601A (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112451517A (en) | Application of epigallocatechin 3-O- (3-O-methyl) gallate in preparing anti-coronavirus medicine | |
| CN106176617B (en) | Amoxicillin soluble powder and preparation method thereof | |
| CN102846641B (en) | Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry | |
| CN105748529A (en) | Combination with effect of inhibiting benign prostatic hyperplasia and application thereof | |
| CN102860984B (en) | Method for preparing compound sulfachloropyridazine sodium powder | |
| CN105193709B (en) | A kind of enrofloxacin injection and preparation method thereof | |
| CN103083347B (en) | Preparation method of veterinary albendazole ivermectin powder | |
| CN103239422A (en) | Preparation method of smellless coated enrofloxacin preparation | |
| CN106474132B (en) | Application of the Polaprezinc in preparation treatment or mitigation caused by radiotherapy and chemotherapy intestinal complications and irritable bowel syndrome drug | |
| CN103536601B (en) | Preparation method of medicine used for controlling pasteurella infection of livestock and poultry | |
| CN103536602B (en) | Medicine used for controlling pasteurella infection of livestock and poultry | |
| CN103126982A (en) | Novel veterinary medicament meglumine enrofloxacin injection and preparation method thereof | |
| CN103721240B (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN117379378A (en) | Compound amoxicillin soluble powder for livestock and preparation process thereof | |
| CN105534937A (en) | Cefadroxil tablet and preparation method thereof | |
| CN100548306C (en) | A kind of injection and preparation technology thereof who treats eperythrozoonosis of domestic animal | |
| CN103520267A (en) | Wettable experimental pullorum evapotranspiration and preparation method thereof | |
| CN101536983A (en) | Albendazole oxide hydrochloride premix for animals | |
| CN103599119A (en) | Preparation method of veterinary albendazole/ivermectin dry suspension | |
| CN103599118A (en) | Veterinary albendazole/ivermectin dry suspension | |
| CN107669700A (en) | A kind of medicine for treating ulcerative colitis and preparation method thereof | |
| CN103083414A (en) | Traditional Chinese medicine composition used for enhancing chicken immunity | |
| CN117323329A (en) | Triclabendazole-levamisole compound dry suspension and preparation method thereof | |
| CN113842415A (en) | Preparation process and application of pulsatilla chinensis soluble powder | |
| CN102423309B (en) | Drug composition for treating vomiting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150513 Termination date: 20150924 |
|
| EXPY | Termination of patent right or utility model |